Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.01. | Arcutis Biotherapeutics, Inc.: ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids | 290 | GlobeNewswire (Europe) | New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE... ► Artikel lesen | |
14.01. | Arcutis Biotherapeutics, Inc.: Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program | 309 | GlobeNewswire (Europe) | Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks85% achieved measurable... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
GAMESTOP | 433 |
EVOTEC | 400 |
TUI | 303 |
NVIDIA | 243 |
DEUTSCHE BANK | 224 |
BAYER | 217 |
NEL | 204 |
PLUG POWER | 201 |
RHEINMETALL | 181 |
SIEMENS ENERGY | 171 |
COMMERZBANK | 157 |
BARRICK GOLD | 141 |
TESLA | 141 |
BASF | 137 |
VOLKSWAGEN | 135 |
DEUTSCHE LUFTHANSA | 130 |
RWE | 130 |
BYD | 124 |
ALLIANZ | 118 |
DEUTSCHE TELEKOM | 118 |
MERCEDES-BENZ | 108 |
RENK GROUP | 106 |
E.ON | 105 |
ALIBABA | 104 |
REDCARE PHARMACY | 104 |